Thank you for the question.
What I would say from a national security threat perspective sort of dovetails to the question you were referring to my CSIS colleagues a moment ago. Obviously, national security covers a broad swath of areas.
In light of the pandemic that we just went through, all of a sudden issues of manufacturing in personal protective equipment, or indeed biopharma, have increased in terms of interest. Analysis is being done when it comes to investment in those areas, absolutely. That comes to bear in terms of our analysis when we're looking at various investments to decide whether or not they pose a threat to supply chains or things of that nature.